Trials / Completed
CompletedNCT01014247
Influence of Moxifloxacin on QTc Interval in Healthy Subjects for Positive Control Validation
A Randomized, Double-blind, 2-way Crossover, Placebo-controlled Study to Investigate the Influence of a Single-dose of Moxifloxacin on the QTc Interval in Healthy Male and Female Subjects for Positive Control Validation in Selected Centers of the PATENT-1 Trial
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to investigate the effect of moxifloxacin on the QT interval in order to gain information on the validity of results that will be collected during another clinical study testing riociguat in patients with pulmonary arterial hypertension (PATENT-1 study).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelox (Moxifloxacin, BAY12-8039) | Single dose of 400 mg |
| DRUG | Placebo | Single dose of matching tablet |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-11-16
- Last updated
- 2013-06-03
Locations
6 sites across 4 countries: Australia, Germany, Singapore, United Kingdom
Source: ClinicalTrials.gov record NCT01014247. Inclusion in this directory is not an endorsement.